RU94030722A - Аэрозольная фармацевтическая композиция, лекарственное средство с модифицированной поверхностью, баллон для доставки фармацевтической композиции, ингалятор, способ лечения респираторных заболеваний - Google Patents
Аэрозольная фармацевтическая композиция, лекарственное средство с модифицированной поверхностью, баллон для доставки фармацевтической композиции, ингалятор, способ лечения респираторных заболеванийInfo
- Publication number
- RU94030722A RU94030722A RU94030722/14A RU94030722A RU94030722A RU 94030722 A RU94030722 A RU 94030722A RU 94030722/14 A RU94030722/14 A RU 94030722/14A RU 94030722 A RU94030722 A RU 94030722A RU 94030722 A RU94030722 A RU 94030722A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- inhalator
- balloon
- respiratory disease
- modified surface
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Abstract
Изобретение относится к аэрозольным композициям, используемым для введения лекарственных средств с помощью ингаляции, в частности фармацевтической аэрозольной композиции, которая включает измельченное лекарство, выбранное из группы, состоящей из сальметерола, сальбутамола, флютиказон пропионата, беклометазон дипропионата и их фармацевтически приемлемых солей и сольватов, и фторуглеводородного или водородсодержащего хлорфторуглеводородного пропеллента, причем препарат практически не содержит ПАВ. Описан также способ лечения респираторных заболеваний, который включает введение ингаляцией эффективного количества фармацевтического аэрозольного препарата, описанного выше.
Claims (1)
- Изобретение относится к аэрозольным композициям, используемым для введения лекарственных средств с помощью ингаляции, в частности фармацевтической аэрозольной композиции, которая включает измельченное лекарство, выбранное из группы, состоящей из сальметерола, сальбутамола, флютиказон пропионата, беклометазон дипропионата и их фармацевтически приемлемых солей и сольватов, и фторуглеводородного или водородсодержащего хлорфторуглеводородного пропеллента, причем препарат практически не содержит ПАВ. Описан также способ лечения респираторных заболеваний, который включает введение ингаляцией эффективного количества фармацевтического аэрозольного препарата, описанного выше.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9126405.1 | 1991-12-12 | ||
GB9126378.0 | 1991-12-12 | ||
GB919126405A GB9126405D0 (en) | 1991-12-12 | 1991-12-12 | Medicaments |
GB919126378A GB9126378D0 (en) | 1991-12-12 | 1991-12-12 | Medicaments |
GB9202522.0 | 1992-02-06 | ||
GB929202522A GB9202522D0 (en) | 1992-02-06 | 1992-02-06 | Medicaments |
PCT/EP1992/002808 WO1993011743A1 (en) | 1991-12-12 | 1992-12-04 | Medicaments |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98118908/14A Division RU2179037C2 (ru) | 1991-12-12 | 1992-12-04 | Баллон для доставки фармацевтического состава, дозирующий ингалятор |
Publications (2)
Publication Number | Publication Date |
---|---|
RU94030722A true RU94030722A (ru) | 1996-10-20 |
RU2129424C1 RU2129424C1 (ru) | 1999-04-27 |
Family
ID=27265965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98118908/14A RU2179037C2 (ru) | 1991-12-12 | 1992-12-04 | Баллон для доставки фармацевтического состава, дозирующий ингалятор |
RU94030722A RU2129424C1 (ru) | 1991-12-12 | 1992-12-04 | Аэрозольная фармацевтическая композиция, способ лечения респираторных заболеваний |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98118908/14A RU2179037C2 (ru) | 1991-12-12 | 1992-12-04 | Баллон для доставки фармацевтического состава, дозирующий ингалятор |
Country Status (30)
Country | Link |
---|---|
US (10) | US5674472A (ru) |
EP (8) | EP1440686B1 (ru) |
JP (2) | JP3026840B2 (ru) |
KR (1) | KR100278339B1 (ru) |
AP (1) | AP402A (ru) |
AT (7) | ATE296617T1 (ru) |
AU (1) | AU663904C (ru) |
BG (3) | BG64539B1 (ru) |
CA (7) | CA2402300C (ru) |
CY (6) | CY2134B1 (ru) |
CZ (1) | CZ287039B6 (ru) |
DE (8) | DE122006000020I1 (ru) |
DK (7) | DK0616523T3 (ru) |
ES (7) | ES2319873T3 (ru) |
GE (1) | GEP20002253B (ru) |
GR (1) | GR3036476T3 (ru) |
HK (3) | HK1004711A1 (ru) |
HU (3) | HU227383B1 (ru) |
IL (1) | IL104068A (ru) |
IS (1) | IS1709B (ru) |
MX (1) | MX9207205A (ru) |
MY (1) | MY109758A (ru) |
NO (3) | NO307864B1 (ru) |
NZ (1) | NZ246044A (ru) |
OA (1) | OA09926A (ru) |
PT (6) | PT1440686E (ru) |
RU (2) | RU2179037C2 (ru) |
SK (1) | SK279920B6 (ru) |
TW (1) | TW232654B (ru) |
WO (1) | WO1993011743A1 (ru) |
Families Citing this family (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5776434A (en) * | 1988-12-06 | 1998-07-07 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
EP0587790B2 (en) | 1991-06-10 | 2000-03-08 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
CA2421976C (en) | 1991-12-12 | 2004-04-20 | Glaxo Group Limited | Medicaments |
US5683676A (en) * | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
US5744123A (en) * | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
US5674471A (en) * | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
US5916540A (en) * | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
AU663906B2 (en) * | 1991-12-12 | 1995-10-26 | Glaxo Group Limited | Medicaments |
US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
US20030103907A1 (en) * | 1991-12-18 | 2003-06-05 | Schultz Robert K. | Suspension aerosol formulations |
US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
US7101534B1 (en) | 1991-12-18 | 2006-09-05 | 3M Innovative Properties Company | Suspension aerosol formulations |
JP3908269B2 (ja) | 1991-12-18 | 2007-04-25 | スリーエム カンパニー | 懸濁エアゾール製剤 |
US5833950A (en) * | 1992-07-31 | 1998-11-10 | Glaxo Group Limited | Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate |
DE69324161T2 (de) * | 1992-12-09 | 1999-10-28 | Boehringer Ingelheim Pharma | Stabilisierte medizinische aerosollösungen |
US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
CA2159498A1 (en) * | 1993-04-01 | 1994-10-13 | Younsik Cha | Method for preparing drugs to treat dermal disorders |
US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
PE44995A1 (es) * | 1994-01-27 | 1995-12-18 | Schering Corp | Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias |
GB9425160D0 (en) * | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
US6013245A (en) * | 1995-01-26 | 2000-01-11 | Glaxo Group Limited | Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant |
GB9507768D0 (en) * | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus |
ATE250439T1 (de) * | 1995-04-14 | 2003-10-15 | Smithkline Beecham Corp | Dosierinhalator für salmeterol |
JPH11503352A (ja) | 1995-04-14 | 1999-03-26 | グラクソ、ウェルカム、インコーポレーテッド | プロピオン酸フルチカゾン用計量投与用吸入器 |
JP3573213B2 (ja) * | 1995-04-14 | 2004-10-06 | グラクソ、ウェルカム、インコーポレーテッド | ベクロメタゾンジプロピオネート用計量投与用吸入器 |
CZ292578B6 (cs) | 1995-04-14 | 2003-10-15 | Glaxo Wellcome Inc. | Inhalátor, inhalační systém |
US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
GB9526392D0 (en) | 1995-12-22 | 1996-02-21 | Glaxo Group Ltd | Medicaments |
GB9612297D0 (en) * | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
US6054488A (en) * | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
GB9622173D0 (en) * | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
DE19652790A1 (de) * | 1996-12-18 | 1998-06-25 | Hermes Fabrik Pharm Praeparate | Pharmazeutische Zubereitungen |
GB9626960D0 (en) * | 1996-12-27 | 1997-02-12 | Glaxo Group Ltd | Valve for aerosol container |
US6054487A (en) * | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
JP2002504091A (ja) * | 1997-03-18 | 2002-02-05 | ベーアーエスエフ アクツィエンゲゼルシャフト | コルチコステロイドに対する応答性を調整するための方法及び組成物 |
US6129905A (en) * | 1997-04-21 | 2000-10-10 | Aeropharm Technology, Inc. | Aerosol formulations containing a sugar as a dispersant |
US5891419A (en) * | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe flunisolide aerosol formulations for oral inhalation |
US5891420A (en) * | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation |
US6120752A (en) * | 1997-05-21 | 2000-09-19 | 3M Innovative Properties Company | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US20030103906A1 (en) * | 1997-10-14 | 2003-06-05 | Smithkline Beecham Corporation | Metered dose inhaler having internal surfaces coated with fluorocarbon polymer |
GB2332372B (en) * | 1997-12-08 | 2002-08-14 | Minnesota Mining & Mfg | Pharmaceutical aerosol compositions |
US6086376A (en) * | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
US6264923B1 (en) | 1998-05-13 | 2001-07-24 | 3M Innovative Properties Company | Medicinal aerosol formulation of ciclesonide and related compounds |
US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
US6458338B1 (en) | 1998-09-22 | 2002-10-01 | Aeropharm Technology Incorporated | Amino acid stabilized medicinal aerosol formulations |
DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
ES2193069T3 (es) | 1999-04-14 | 2003-11-01 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol. |
US20100197719A1 (en) * | 1999-05-12 | 2010-08-05 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
US20040002548A1 (en) * | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
JP2003509359A (ja) | 1999-09-11 | 2003-03-11 | グラクソ グループ リミテッド | プロピオン酸フルチカゾンの医薬製剤 |
GB2385596B (en) * | 1999-09-11 | 2004-03-03 | Glaxo Group Ltd | Container for pharmaceutical formulation of fluticasone propionate |
GB9924992D0 (en) * | 1999-10-21 | 1999-12-22 | Glaxo Group Ltd | Pharmaceutical aerosol formulations |
DE60019167T2 (de) * | 1999-12-24 | 2006-05-11 | Glaxo Group Ltd., Greenford | Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason |
IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
TWI290473B (en) | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
BR0015884A (pt) | 2000-05-22 | 2003-07-08 | Chiesi Farma Spa | Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados |
EP1284771B1 (en) | 2000-05-23 | 2005-12-14 | Glaxo Group Limited | Aerosol container for formulations of salmeterol xinafoate |
GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
WO2002005059A2 (en) * | 2000-07-07 | 2002-01-17 | Baxter International Inc. | Medical system, method and apparatus employing mems |
AR030516A1 (es) * | 2000-08-31 | 2003-08-20 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
FI20002177A0 (fi) * | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
FI20002216A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
EP1335661B1 (en) | 2000-10-27 | 2009-05-06 | Baxter Healthcare S.A. | Production of microspheres |
NZ526564A (en) | 2000-12-22 | 2004-12-24 | Glaxo Group Ltd | Metered dose inhaler for salmeterol xinafoate |
US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
EP1353647B1 (en) | 2000-12-27 | 2011-03-23 | Gilead Sciences, Inc. | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
DE10104370A1 (de) * | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen mit geringeren Nebenwirkungen |
GB0106046D0 (en) | 2001-03-12 | 2001-05-02 | Glaxo Group Ltd | Canister |
IL157580A0 (en) * | 2001-03-20 | 2004-03-28 | Glaxo Group Ltd | Inhalation drug combination |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US6455028B1 (en) * | 2001-04-23 | 2002-09-24 | Pharmascience | Ipratropium formulation for pulmonary inhalation |
BR0209986A (pt) * | 2001-05-25 | 2004-04-06 | Pfizer | Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias |
PT1273292E (pt) | 2001-07-02 | 2004-10-29 | Chiesi Farma Spa | Formulacao optimizada de tobramicina para aerossolizacao |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
GB0124523D0 (en) * | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
US7931022B2 (en) * | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
US20030191151A1 (en) * | 2001-10-26 | 2003-10-09 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
JP2003221335A (ja) | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
US20030203930A1 (en) * | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US6702997B2 (en) | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
US20030140920A1 (en) * | 2001-10-26 | 2003-07-31 | Dey L.P. | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
WO2003053411A1 (en) | 2001-12-19 | 2003-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
CA2475092C (en) | 2002-02-04 | 2012-05-01 | Christian F. Wertz | Nanoparticulate compositions having lysozyme as a surface stabilizer |
US7582284B2 (en) * | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
US7378438B2 (en) * | 2002-04-19 | 2008-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
WO2004037843A2 (en) * | 2002-10-25 | 2004-05-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
WO2004060260A2 (en) * | 2002-12-18 | 2004-07-22 | Glaxo Group Limited | Drug delivery system with vented mouthpiece |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
US7459146B2 (en) | 2003-05-30 | 2008-12-02 | 3M Innovative Properties Company | Stabilized aerosol dispersions |
EP1635845A1 (en) | 2003-06-13 | 2006-03-22 | ALTANA Pharma AG | Formoterol and ciclesonide combination |
SE527069C2 (sv) * | 2003-06-19 | 2005-12-13 | Mederio Ag | Förfarande och anordning för administrering av läkemedelspulver |
SE527190C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
SE527189C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel |
SE526509C2 (sv) * | 2003-06-19 | 2005-09-27 | Microdrug Ag | Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd |
SE527200C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av formaterol och fluticason |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
US20050043343A1 (en) * | 2003-07-28 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
US20080118442A1 (en) * | 2003-09-10 | 2008-05-22 | Map Pharmaceuticals, Inc. | Aerosol Formulations for Delivery of Dihydroergotamine to the Systemic Circulations Via Pulmonary Inhalation |
EP1670482B2 (en) | 2003-09-16 | 2022-06-29 | Covis Pharma B.V. | Use of ciclesonide for the treatment of respiratory diseases |
BRPI0415707A (pt) * | 2003-10-20 | 2006-12-19 | Schering Corp | composições farmacêuticas |
US9308199B2 (en) * | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
SE0303269L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medicinsk produkt |
SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
ES2391563T5 (es) | 2004-07-02 | 2022-10-26 | Boehringer Ingelheim Int | Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor |
PE20061162A1 (es) * | 2004-12-06 | 2006-10-14 | Smithkline Beecham Corp | Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos |
EP1828100A1 (en) | 2004-12-17 | 2007-09-05 | Cipla Ltd. | Pharmaceutical compounds and compositions |
CN101175479A (zh) * | 2005-03-16 | 2008-05-07 | 霍尼韦尔国际公司 | 药物递送制剂、装置和方法 |
JP2008538758A (ja) * | 2005-04-23 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬に加えてベータ受容体刺激薬及びステロイドを含有する吸入用の医薬組成物 |
US20060239935A1 (en) * | 2005-04-23 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Compositions for inhalation |
TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
DE102006017320A1 (de) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel |
US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
EP2425820B1 (en) | 2007-02-11 | 2015-04-08 | MAP Pharmaceuticals Inc | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
GB0712454D0 (en) | 2007-06-27 | 2007-08-08 | Generics Uk Ltd | Pharmaceutical compositions |
GB0716026D0 (en) * | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
WO2009088553A1 (en) | 2007-10-22 | 2009-07-16 | Board Of Regents, The University Of Texas System | Dry powder drug delivery formulations, methods of use, and devices therefore |
WO2009059219A2 (en) * | 2007-11-02 | 2009-05-07 | Wayne State University | Method of engineering polar drug particles with surface-trapped hydrofluoroalkane-philes |
US8227027B2 (en) | 2007-12-07 | 2012-07-24 | Presspart Gmbh & Co. Kg | Method for applying a polymer coating to an internal surface of a container |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
AU2009244058B2 (en) | 2008-05-09 | 2015-07-02 | Nuvaira, Inc | Systems, assemblies, and methods for treating a bronchial tree |
NZ594323A (en) | 2009-01-23 | 2013-05-31 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway |
JP2012528889A (ja) * | 2009-06-05 | 2012-11-15 | アーシエックス セラピューティックス, インコーポレイテッド | フルチカゾンの眼科処方物および使用方法 |
EP4193948A1 (en) | 2009-10-27 | 2023-06-14 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
AU2010319477A1 (en) | 2009-11-11 | 2012-05-24 | Holaira, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
EP2528601A1 (en) | 2010-01-26 | 2012-12-05 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Compositions and methods for prevention and treatment of pulmonary hypertension |
CN102416179B (zh) | 2010-09-28 | 2014-05-07 | 益得生物科技股份有限公司 | 用于哮喘的吸入性复方组合物 |
TWI399202B (zh) | 2011-03-17 | 2013-06-21 | Intech Biopharm Ltd | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
US20140113877A1 (en) | 2011-06-15 | 2014-04-24 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds |
CN103582644B (zh) | 2011-06-17 | 2016-07-20 | 塔科达有限责任公司 | 酞嗪酮-吡咯并嘧啶羧酰胺衍生物 |
GB201118188D0 (en) * | 2011-10-21 | 2011-12-07 | 3M Innovative Properties Co | Manufacture of medicinal aerosol canisters |
GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
US8877967B2 (en) | 2012-03-23 | 2014-11-04 | Oxigene, Inc. | Compositions and methods for inhibition of cathepsins |
RU2494730C1 (ru) * | 2012-03-27 | 2013-10-10 | Шолекс Девелопмент Гмбх | Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
EP3174522A1 (en) | 2014-07-29 | 2017-06-07 | 3M Innovative Properties Company | Method of preparing a pharmaceutical composition |
WO2018069210A1 (en) | 2016-10-10 | 2018-04-19 | Takeda Gmbh | Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4 |
US10702495B2 (en) | 2017-02-20 | 2020-07-07 | Nexien Biopharma, Inc. | Method and compositions for treating dystrophies and myotonia |
WO2020092845A1 (en) | 2018-11-01 | 2020-05-07 | Rigel Pharmaceuticals, Inc. | Method and composition embodiments for treating acute myeloid leukemia |
US20200377518A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
EP3750528A1 (en) | 2019-06-11 | 2020-12-16 | Nexien Biopharma, Inc. | Compositions for treating dystrophies and myotonia |
BR112022001418A2 (pt) | 2019-08-08 | 2022-06-07 | Rigel Pharmaceuticals Inc | Compostos e método para tratar a síndrome de liberação de citocinas |
MX2022001890A (es) | 2019-08-14 | 2022-04-26 | Rigel Pharmaceuticals Inc | Metodo para bloquear o mejorar el sindrome de liberacion de citocinas. |
TW202346291A (zh) | 2022-03-23 | 2023-12-01 | 美商雷傑製藥公司 | 作為irak抑制劑的嘧啶—2—基—吡唑化合物 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (ru) * | 1956-03-21 | 1900-01-01 | ||
US2885427A (en) * | 1956-11-15 | 1959-05-05 | Dow Chemical Co | Fluorination of trichloroethylene |
BE556587A (ru) * | 1957-01-31 | 1957-04-11 | ||
NL289785A (ru) † | 1962-11-29 | |||
US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
US3261748A (en) | 1964-07-17 | 1966-07-19 | Dow Chemical Co | 1,1,1,2-tetrafluoroethane anesthetic |
US4044126A (en) * | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) * | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US3895111A (en) * | 1973-06-27 | 1975-07-15 | American Cyanamid Co | Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate |
US3809294A (en) * | 1973-06-27 | 1974-05-07 | American Cyanamid Co | Dispensing lung contacting powdered medicaments |
US4044125A (en) * | 1975-07-18 | 1977-08-23 | Eli Lilly And Company | Method of stabilizing acetylsalicylic acid in the presence of d-propoxyphene hydrochloride and compositions thereof |
US4405598A (en) * | 1976-01-30 | 1983-09-20 | Fisons, Limited | Composition for treating asthma |
FI770215A (ru) * | 1976-01-30 | 1977-07-31 | Fisons Ltd | |
NL7708731A (nl) † | 1976-08-13 | 1978-02-15 | Montedison Spa | Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen. |
US4117958A (en) * | 1976-12-27 | 1978-10-03 | Spitzer Joseph G | Vapor tap valve for aerosol containers used with flammable propellants |
CY1291A (en) † | 1980-02-15 | 1985-10-18 | Glaxo Group Ltd | Androstane 17 beta carbothioates |
CA1201114A (en) * | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
US4578221A (en) * | 1980-04-23 | 1986-03-25 | Glaxo Group Limited | Androstane carbothioic acids |
FI63672C (fi) * | 1980-05-19 | 1983-08-10 | Orion Yhtymae Oy | Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan |
GB8432063D0 (en) * | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
GB8820398D0 (en) | 1988-08-27 | 1988-09-28 | Fisons Plc | Pharmaceutical formulation |
US5776434A (en) * | 1988-12-06 | 1998-07-07 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8828477D0 (en) † | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
GB8900267D0 (en) * | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
DE3905726A1 (de) * | 1989-02-24 | 1990-08-30 | Hoechst Ag | Druckgaspackung und treibmittel fuer aerosole |
US4940171A (en) * | 1989-05-18 | 1990-07-10 | Gilroy Gordon C | Aerosol package having compressed gas propellant and vapor tap of minute size |
IL95590A (en) * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
GB2235627B (en) † | 1989-09-08 | 1993-09-01 | Glaxo Group Ltd | Inhalation medicaments for treating respiratory disorders |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
GB8921222D0 (en) † | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
US5439670A (en) * | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
DE4003270A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgase und ihre verwendung in arzneimittelzubereitungen |
IL97065A (en) * | 1990-02-02 | 1994-01-25 | Fisons Plc | Repellent preparations for aerosol |
DE4003272A1 (de) † | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
WO1991014422A1 (en) * | 1990-03-23 | 1991-10-03 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5118494A (en) * | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
ATE196076T1 (de) * | 1990-06-28 | 2000-09-15 | Glaxo Wellcome Inc | Aerosol arzneiformulierungen |
US5126123A (en) * | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
AU8055691A (en) * | 1990-06-29 | 1992-01-23 | Fisons Plc | Pressurised aerosol compositions |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
DK0553298T3 (da) * | 1990-10-18 | 1995-04-18 | Minnesota Mining & Mfg | Aerosolformulering omfattende beclomethason-17,21-dipropionat |
GB9024366D0 (en) * | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
GB9024365D0 (en) † | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
US5290539A (en) * | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
US5182097A (en) † | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US5190029A (en) * | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
EP0504112A3 (en) † | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
JPH04316448A (ja) * | 1991-04-12 | 1992-11-06 | Iwatani Internatl Corp | 人参微粉末の製造方法 |
EP0587790B2 (en) * | 1991-06-10 | 2000-03-08 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
DK0656206T3 (da) * | 1991-06-10 | 2001-10-08 | Schering Corp | Aerosolformuleringer uden chlorfluorcarbonforbindelser |
US5683676A (en) | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
AU663906B2 (en) † | 1991-12-12 | 1995-10-26 | Glaxo Group Limited | Medicaments |
US5744123A (en) | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
US5916540A (en) | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
US5674471A (en) * | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
CA2421976C (en) * | 1991-12-12 | 2004-04-20 | Glaxo Group Limited | Medicaments |
US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
US20030103907A1 (en) * | 1991-12-18 | 2003-06-05 | Schultz Robert K. | Suspension aerosol formulations |
JP3908269B2 (ja) * | 1991-12-18 | 2007-04-25 | スリーエム カンパニー | 懸濁エアゾール製剤 |
US5202110A (en) * | 1992-01-22 | 1993-04-13 | Virginia Commonwealth University | Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
GB9202519D0 (en) | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
US5833950A (en) | 1992-07-31 | 1998-11-10 | Glaxo Group Limited | Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate |
JPH0855956A (ja) | 1994-08-10 | 1996-02-27 | Fuji Electric Co Ltd | 駆動回路装置モジュール |
US6013245A (en) * | 1995-01-26 | 2000-01-11 | Glaxo Group Limited | Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant |
GB9510750D0 (en) | 1995-05-26 | 1995-07-19 | Zeneca Ltd | Chemical process |
US5603918A (en) * | 1995-06-09 | 1997-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aerosol composition of a salt of ipratropium and a salt of albuterol |
TW382127B (en) * | 1996-08-30 | 2000-02-11 | Sony Corp | Magnetic recording medium and cleaning tape |
US6306396B1 (en) * | 1996-10-01 | 2001-10-23 | Corixa Corporation | Compounds and methods for the diagnosis and treatment of B. microti infection |
IL157580A0 (en) * | 2001-03-20 | 2004-03-28 | Glaxo Group Ltd | Inhalation drug combination |
-
1992
- 1992-02-11 IL IL10406892A patent/IL104068A/en not_active IP Right Cessation
- 1992-12-04 JP JP5510573A patent/JP3026840B2/ja not_active Expired - Lifetime
- 1992-12-04 PT PT04007494T patent/PT1440686E/pt unknown
- 1992-12-04 EP EP04007494A patent/EP1440686B1/en not_active Expired - Lifetime
- 1992-12-04 HU HU9401742A patent/HU227383B1/hu unknown
- 1992-12-04 SK SK674-94A patent/SK279920B6/sk not_active IP Right Cessation
- 1992-12-04 DE DE200612000020 patent/DE122006000020I1/de active Pending
- 1992-12-04 ES ES02079709T patent/ES2319873T3/es not_active Expired - Lifetime
- 1992-12-04 EP EP99204248A patent/EP0990437B2/en not_active Expired - Lifetime
- 1992-12-04 ES ES96202592T patent/ES2158988T3/es not_active Expired - Lifetime
- 1992-12-04 EP EP02077251A patent/EP1275375B1/en not_active Expired - Lifetime
- 1992-12-04 NZ NZ246044A patent/NZ246044A/en not_active IP Right Cessation
- 1992-12-04 CA CA002402300A patent/CA2402300C/en not_active Expired - Lifetime
- 1992-12-04 DK DK92924667T patent/DK0616523T3/da active
- 1992-12-04 PT PT00202961T patent/PT1066828E/pt unknown
- 1992-12-04 DK DK04007494T patent/DK1440686T3/da active
- 1992-12-04 HU HU0800468A patent/HU227681B1/hu unknown
- 1992-12-04 DK DK02077251T patent/DK1275375T3/da active
- 1992-12-04 EP EP07115933A patent/EP1857101A3/en not_active Withdrawn
- 1992-12-04 CZ CZ19941430A patent/CZ287039B6/cs not_active IP Right Cessation
- 1992-12-04 CA CA002303685A patent/CA2303685C/en not_active Expired - Lifetime
- 1992-12-04 CA CA002447510A patent/CA2447510C/en not_active Expired - Lifetime
- 1992-12-04 AT AT02077251T patent/ATE296617T1/de active
- 1992-12-04 EP EP00202961A patent/EP1066828B9/en not_active Expired - Lifetime
- 1992-12-04 DE DE69232856T patent/DE69232856T3/de not_active Expired - Lifetime
- 1992-12-04 ES ES92924667T patent/ES2113444T3/es not_active Expired - Lifetime
- 1992-12-04 DE DE69231857T patent/DE69231857T2/de not_active Expired - Lifetime
- 1992-12-04 PT PT99204248T patent/PT990437E/pt unknown
- 1992-12-04 ES ES04007494T patent/ES2294386T3/es not_active Expired - Lifetime
- 1992-12-04 EP EP92924667A patent/EP0616523B1/en not_active Expired - Lifetime
- 1992-12-04 AT AT04007494T patent/ATE373465T1/de active
- 1992-12-04 PT PT02079709T patent/PT1287820E/pt unknown
- 1992-12-04 CA CA002125667A patent/CA2125667C/en not_active Expired - Lifetime
- 1992-12-04 ES ES00202961T patent/ES2199739T5/es not_active Expired - Lifetime
- 1992-12-04 AT AT02079709T patent/ATE421315T1/de active
- 1992-12-04 AU AU30850/92A patent/AU663904C/en not_active Expired
- 1992-12-04 KR KR1019940702000A patent/KR100278339B1/ko not_active IP Right Cessation
- 1992-12-04 EP EP02079709A patent/EP1287820B1/en not_active Expired - Lifetime
- 1992-12-04 DE DE69224656T patent/DE69224656T2/de not_active Expired - Lifetime
- 1992-12-04 RU RU98118908/14A patent/RU2179037C2/ru active
- 1992-12-04 PT PT02077251T patent/PT1275375E/pt unknown
- 1992-12-04 AT AT92924667T patent/ATE163539T1/de active
- 1992-12-04 DK DK02079709T patent/DK1287820T3/da active
- 1992-12-04 DE DE69233519T patent/DE69233519T2/de not_active Expired - Lifetime
- 1992-12-04 AT AT96202592T patent/ATE201587T1/de active
- 1992-12-04 ES ES02077251T patent/ES2242823T3/es not_active Expired - Lifetime
- 1992-12-04 GE GEAP19922652A patent/GEP20002253B/en unknown
- 1992-12-04 DK DK96202592T patent/DK0756868T3/da active
- 1992-12-04 DE DE69233076T patent/DE69233076T3/de not_active Expired - Lifetime
- 1992-12-04 AT AT99204248T patent/ATE227975T1/de active
- 1992-12-04 CA CA002654849A patent/CA2654849A1/en not_active Abandoned
- 1992-12-04 AT AT00202961T patent/ATE240716T1/de active
- 1992-12-04 EP EP96202592A patent/EP0756868B1/en not_active Expired - Lifetime
- 1992-12-04 WO PCT/EP1992/002808 patent/WO1993011743A1/en active IP Right Grant
- 1992-12-04 DE DE69233755T patent/DE69233755D1/de not_active Expired - Lifetime
- 1992-12-04 PT PT96202592T patent/PT756868E/pt unknown
- 1992-12-04 RU RU94030722A patent/RU2129424C1/ru active
- 1992-12-04 ES ES99204248T patent/ES2188092T5/es not_active Expired - Lifetime
- 1992-12-04 DK DK99204248T patent/DK0990437T4/da active
- 1992-12-04 CA CA002362539A patent/CA2362539C/en not_active Expired - Fee Related
- 1992-12-04 DE DE69233712T patent/DE69233712T2/de not_active Expired - Lifetime
- 1992-12-04 CA CA002586146A patent/CA2586146C/en not_active Expired - Lifetime
- 1992-12-04 DK DK00202961T patent/DK1066828T4/da active
- 1992-12-11 IS IS3957A patent/IS1709B/is unknown
- 1992-12-11 AP APAP/P/1992/000461A patent/AP402A/en active
- 1992-12-11 MX MX9207205A patent/MX9207205A/es unknown
- 1992-12-11 MY MYPI92002297A patent/MY109758A/en unknown
- 1992-12-14 TW TW081110012A patent/TW232654B/zh not_active IP Right Cessation
-
1994
- 1994-05-19 OA OA60516A patent/OA09926A/en unknown
- 1994-05-30 BG BG102689A patent/BG64539B1/bg unknown
- 1994-05-30 BG BG102689/98A patent/BG102689A/xx unknown
- 1994-05-30 BG BG98803A patent/BG62119B1/bg unknown
- 1994-06-10 NO NO942185A patent/NO307864B1/no not_active IP Right Cessation
-
1995
- 1995-05-19 US US08/444,919 patent/US5674472A/en not_active Expired - Lifetime
- 1995-05-19 US US08/444,743 patent/US5676929A/en not_active Expired - Lifetime
- 1995-06-22 HU HU95P/P00331P patent/HU211671A9/hu unknown
-
1997
- 1997-06-17 US US08/877,198 patent/US6251368B1/en not_active Expired - Fee Related
-
1998
- 1998-04-16 HK HK98103184A patent/HK1004711A1/xx not_active IP Right Cessation
- 1998-04-16 HK HK98112894A patent/HK1012988A1/xx not_active IP Right Cessation
-
1999
- 1999-03-11 JP JP11064667A patent/JPH11310533A/ja active Pending
- 1999-09-03 CY CY9900027A patent/CY2134B1/xx unknown
- 1999-11-02 US US09/431,872 patent/US6238647B1/en not_active Expired - Fee Related
-
2000
- 2000-03-09 NO NO20001227A patent/NO325422B1/no not_active IP Right Cessation
- 2000-06-14 US US09/593,380 patent/US6303103B1/en not_active Expired - Fee Related
-
2001
- 2001-06-21 US US09/885,133 patent/US20020028183A1/en not_active Abandoned
- 2001-08-30 GR GR20010401335T patent/GR3036476T3/el unknown
-
2003
- 2003-03-11 US US10/384,568 patent/US20030143163A1/en not_active Abandoned
- 2003-07-15 HK HK03105126.3A patent/HK1054500B/zh not_active IP Right Cessation
- 2003-12-19 US US10/739,072 patent/US20040136920A1/en not_active Abandoned
-
2004
- 2004-05-11 CY CY0400037A patent/CY2441B1/xx unknown
- 2004-11-05 CY CY0400078A patent/CY2493B1/xx unknown
- 2004-11-23 US US10/994,318 patent/US7498020B2/en not_active Expired - Fee Related
-
2006
- 2006-10-24 CY CY0600029A patent/CY2566B1/xx unknown
- 2006-11-06 NO NO20065102A patent/NO20065102L/no unknown
-
2008
- 2008-04-02 CY CY0800006A patent/CY2591B2/xx unknown
-
2009
- 2009-01-16 US US12/320,115 patent/US20090188491A1/en not_active Abandoned
- 2009-04-02 CY CY0900004A patent/CY2602B2/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94030722A (ru) | Аэрозольная фармацевтическая композиция, лекарственное средство с модифицированной поверхностью, баллон для доставки фармацевтической композиции, ингалятор, способ лечения респираторных заболеваний | |
AR002014A1 (es) | Formulacion farmaceutica en aerosol, metodo para su manufactura, y metodo para la manufactura de un medicamento para el tratamiento de enfermedades atraves del tracto respiratorio que contienen a dicha formulacion. | |
Laube | The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination | |
CA2125666A1 (en) | Medicaments | |
JP3818852B2 (ja) | 肺への薬物送達 | |
US7601336B2 (en) | Pharmaceutical aerosol composition | |
KR101312311B1 (ko) | 약학적 코 제형물 및 이의 이용 방법 | |
Acerbi et al. | Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite® technology | |
NO944526L (no) | Medisinsk aerosolformulering | |
GB9425160D0 (en) | Medicaments | |
RU94040361A (ru) | Аэрозольная фармацевтическая композиция, баллончик для доставки композиции, дозировочный ингалятор, способ лечения респираторных заболеваний, способ получения композиции | |
DK0616525T3 (da) | Medikamenter | |
ATE195249T1 (de) | Pharmazeutische aerosol welche mindestens ein zucker enthält | |
HU226694B1 (en) | Medicinal aerosol products containing ciclesonide | |
US20050079136A1 (en) | Aerosol formulations of delta tetrahydrocannabinol | |
DE69002718D1 (de) | Medikamente. | |
EP1244487B1 (en) | Aerosol inhaler | |
KR101312331B1 (ko) | 약학적 코 제형물 및 이의 이용 방법 | |
JPH11502729A (ja) | エーロゾル投与全身麻酔薬 | |
Jenkins | Clinical evaluation of CFC-free metered dose inhalers | |
Woodcock | Continuing patient care with metered-dose inhalers | |
US20030147814A1 (en) | Medicinal aerosol formulations comprising ion pair complexes | |
US2649918A (en) | Pharmaceutical preparations | |
RU2238091C2 (ru) | Способ лечения туберкулеза у человека | |
US20230105232A1 (en) | Dry Powder Foamable Formulations for Deliverhttps://dav.uspto.gov/prex/index.html#domesticContinuityy of Medicaments through the Mucosa |